Orgenesis Inc. P/Operating CF

P/Operating CF of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/Operating CF growth rates and interactive chart. A valuation metric that measures the price of a stock compared to its operating cash flow per share. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low P/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current P/Operating CF of Orgenesis Inc. is -2.12 (as of December 30, 2020)
  • P/Operating CF for the quarter ending September 29, 2021 was -11.76 (a 2.83% increase compared to previous quarter)
  • Year-over-year quarterly P/Operating CF increased by 454.26%
  • Annual P/Operating CF for 2020 was -2.12 (a -92.26% decrease from previous year)
  • Annual P/Operating CF for 2019 was -27.4 (a 87.59% increase from previous year)
  • Annual P/Operating CF for 2018 was -14.6 (a -5.75% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/Operating CF of Orgenesis Inc.

Most recent P/Operating CFof ORGS including historical data for past 10 years.

Interactive Chart of P/Operating CF of Orgenesis Inc.

Orgenesis Inc. P/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -11.76 -11.43 -26.44
2020 -2.12 -11.15 -14.31 -4.93 -2.12
2019 -27.4 -30.54 -18.6 -17.95 -27.4
2018 -14.6 -16.35 -23.53 -40.71 -14.6
2017 -23.81 -31.12 223.4 -32.61
2016 -58.98 -47.27 -17.38 0.0 -58.98
2015 0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.